Hitting the Mark with Targeted Therapy: BRAF, NRAS, CKIT, etc...Sullivan

Ryan J Sullivan, Associte Director of the Melanoma Program at Massachusetts General Hospital Cancer Center, Harvard Medical School discusses the BRAF/MEK therapeutic landscape and new options for triple therapy in Metastatic Melanoma #melanoma #immunotherapy #cancer #PD1 #BRAF #MEK